Ito, Kousei, Tomokazu Koresawa, Koichi Nakano, and Toshiharu Horie. Mrp2 is involved in benzylpenicillin-induced choleresis. Am J Physiol Gastrointest Liver Physiol 287: G42-G49, 2004; 10.1152/ajpgi.00416.2003 180 mol/kg), a classic ␤-lactam antibiotic, was intravenously given to SpragueDawley (SD) rats and multidrug resistance-associated protein 2 (Mrp2)-deficient Eisai hyperbilirubinemic rats (EHBR). A percentage of the [ 3 H]PCG was excreted into the bile of the rats within 60 min (SD rats: 31.7% and EHBR: 4.3%). Remarkably, a transient increase in the bile flow (ϳ2-fold) and a slight increase in the total biliary bilirubin excretion were observed in SD rats but not in the EHBR after PCG administration. This suggests that the biliary excretion of PCG and its choleretic effect are Mrp2-dependent. Positive correlations were observed between the biliary excretion rate of PCG and bile flow (r 2 ϭ 0.768) and more remarkably between the biliary excretion rate of GSH and bile flow (r 2 ϭ 0.968). No ATP-dependent uptake of [ 3 H]PCG was observed in Mrp2-expressing Sf9 membrane vesicles, whereas other forms of Mrp2-substrate transport were stimulated in the presence of PCG. GSH efflux mediated by human MRP2 expressed in Madin-Darby canine kidney II cells was enhanced in the presence of PCG in a concentration-dependent manner. In conclusion, the choleretic effect of PCG is caused by the stimulation of biliary GSH efflux as well as the concentrative biliary excretion of PCG itself, both of which were Mrp2 dependent. bile flow; multidrug resistance-associated protein; ␤-lactam
THE MULTIDRUG RESISTANCE-ASSOCIATED protein (MRP) 2/ATPbinding cassette transporter family C2 (MRP2 for the human gene and Mrp2 for the rat gene are used throughout this manuscript) is highly expressed on the bile canalicular membrane of hepatocytes. It actively excretes structurally diverse organic anions, including GSH (25, 26) , glutathione conjugates, bilirubin glucuronides, sulfated and glucuronidated bile salts, and nonconjugated organic anions that account for most of the bile salt independent flow (BSIDF). The other important carrier for the production of bile flow is the bile salt export pump (BSEP) that also actively excretes monovalent bile salts in an ATP-dependent manner to produce bile salt dependent flow (BSDF) (12) . Alteration of the transport activity of these canalicular transporters will significantly affect bile flow. Internalization of these canalicular transporters will cause cholestasis (7, 24, 27) , whereas reinsertion of these transporters will result in choleresis (20, 21, 30) . Moreover, inhibition of the transport process also induces cholestasis (4, 5, 8) . However, no direct evidence has been reported concerning choleresis due to stimulation of the intrinsic transport activity of these transporters.
Several ␤-lactam antibiotics are known to induce choleresis. Verkade et al. (35) reported that intravenous administration of ampicillin (180 mol/kg) to rats induced choleresis, but this was not observed in Mrp2-deficient TR Ϫ rats. Gonzalez et al. (14) reported that 0.3-3 mmol/kg piperacillin also induced choleresis in rats, and this was mainly explained by the stimulation of BSIDF. Biliary excretion of ␤-lactam antibiotics also appears to be mediated by Mrp2, because excretion in bile was dramatically reduced in Mrp2-deficient rats (29, 35) . These results suggest an interaction of ␤-lactams with Mrp2 acting as substrates and/or stimulators, although the precise mechanism remains to be elucidated.
Recently, MRP2 transport activity was shown to be stimulated by a number of compounds including probenecid, indomethacin, and bile acids (3, 17, 39) . Of these, MRP2-mediated GSH export was reported to be stimulated in the presence of indomethacin, sulfinpyrazone, and vinblastine (11) . Sulfinpyrazone is thought to be a substrate of MRP2 even in the absence of GSH, and it produced further stimulation in the presence of GSH via a cotransport mechanism (11) . Vinblastine is cotransported with GSH, whereas indomethacin is a poor substrate of MRP2. Although no simple explanation is available, multiple sites are considered to be involved in the explanation of those results. Evers and colleagues (6, 11) proposed that MRP2, as well as perhaps MRP1, also has a G-site (GSH binding site) and a D-site (drug binding site). These two sites work by positive cooperation. These hypotheses need to be verified experimentally in the future. Importantly, there is no published report investigating whether such stimulatory compounds also exhibit a choleretic effect in vivo.
In this study, the physiological and pharmacological significance of these stimulatory effects on Mrp2 transport function was examined to help our understanding of the bile formation mechanism. In particular, the choleretic effect of benzylpenicillin (PCG) was studied in vivo and was also examined in vitro using Mrp2/MRP2 expression systems. As a result, we initially demonstrated that a compound that stimulates GSH efflux in vitro actually leads to in vivo choleresis via the stimulation of GSH excretion into bile.
MATERIALS AND METHODS

Chemicals. [phenyl-4(n)-
3 H]PCG (10 -30 Ci/mmol) was purchased from Amersham Pharmacia Biotech (Piscataway, NJ). [ 3 H]dinitrophenyl glutathione (DNP-SG; 50.0 Ci/mmol) was synthesized enzymatically using [glycine-2-3 H]glutathione (New England Nuclear Life Science Products, Boston, MA) and 1-chloro-2,4-dinitrobenzene and glutathione S-transferase (Sigma, St. Louis, MO) as described previously (19) . [ 3 H]17␤-estradiol 17-(␤-D-glucuronide) (E217␤G; 55 Ci/ mmol) was purchased from New England Nuclear Life Science Products. PCG potassium was purchased from Wako Pure Chemical Industries (Osaka, Japan).
Animals. Male Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic rats (EHBR) weighing 240 -300 g (7-8 wk old) were used throughout the experiments (Japan SLC, Shizuoka, Japan).
Blood and bile sampling. SD rats and EHBR were maintained under ether anesthesia, and then the femoral artery and vein were cannulated with polyethylene tubing (PE-50) for PCG administration and blood sampling. The common bile duct was also cannulated with PE-10 tubing. [ 3 H]PCG (180 mol ⅐ ml Ϫ1 ⅐ kg Ϫ1 ; 6.7 Ci/kg) in saline was administered intravenously through the femoral vein cannula. Blood samples were obtained at given times. Plasma and bile concentrations of [ 3 H]PCG were determined by measuring the radioactivity in a liquid scintilation counter (model LSC5000; Aloka, Tokyo, Japan). Retrograde acivicin, an inhibitor of ␥-glutamyl transpeptidase, was preinfused into the bile duct for the determination of GSH in the bile (18) . Briefly, acivicin (Sigma) was dissolved in Krebs-Henseleit buffer (50 mM) and infused for 1 min via the bile cannula (100 l/rat), which was occluded for 1 min and then released for 10 min to allow a constant bile flow rate to be reestablished. PCG or saline was administered after an additional 15 min. Rates of bile flow, bilirubin, and PCG excretion in the bile were unaffected by acivicin pretreatment. All procedures were approved by the animal care committee in our university.
Analysis of bilirubin and GSH in the bile. Direct and indirect bilirubin concentrations of bile were determined by using a kit (bilirubin BII-Test Wako; Wako Pure Chemical Industries). Reduced GSH in bile was determined by a postlabel HPLC method as described previously (18) . Briefly, 10-l bile specimens were directly mixed with ice-cold 990 l 25% metaphosphoric acid-0.1% EDTA and frozen at Ϫ20°C until analysis. This initial treatment minimized the degradation of GSH even in the presence of the bile component. Samples were centrifuged at 20,000 g for 5 min at 4°C, and the resulting supernatants were mixed with 3-fluorotyrosine as an internal standard followed by filtration through a 0.45-m syringe filter (Millex-LH; Millipore, Bedford, MA). HPLC was performed on an Inertsil Octa Decyl Silyl column (4.6 mm inner diameter ϫ 250 mm; GL Sciences, Tokyo, Japan). Elution was performed by using a mobile phase (0.1% trifluoroacetic acid/methanol ϭ 18:1) at a flow rate of 1.0 ml/min. The eluate from the column was mixed with solution containing 18.6 mM O-phthalaldehyde and 17.1 mM 2-mercaptoethanol in 100 mM carbonate buffer (pH 10.5) that was delivered at a rate of 0.2 ml/min. The mixture was then passed through a stainless steel coil at 70°C to facilitate derivatization. A fluorescence detector was used and operated at an excitation wavelength of 355 nm and an emission wavelength of 425 nm. The concentration of GSH was calculated from the ratio of the height of the standard GSH sample.
Vesicle isolation and transport study. Recombinant baculovirus was prepared as described (16) . Sf9 cells were infected with appropriate amounts of the respective virus and cultured for 60 h in the presence of 5% FBS. Membrane vesicles were isolated from 1-2 ϫ 10 8 Sf9 cells using the standard method described previously (16 (16) . Briefly, 16 l transport medium (in mM: 10 Tris, 250 sucrose, 10 MgCl2, 5 ATP or AMP, pH 7.4) was preincubated at 37°C for 3 min and then rapidly mixed with 4 l membrane vesicle suspension (5-10 g) and subsequently incubated for the indicated period. The transport reaction was stopped by the addition of 1 ml ice-cold buffer containing 250 mM sucrose, 100 mM NaCl, and 10 mM Tris ⅐ HCl (pH 7.4). The stopped reaction mixture was passed through a 0.45-m HAWP filter (Millipore) and then washed twice with 5 ml stop solution. Radioactivity retained on the filter was determined by using a liquid scintillation counter (model LSC5000; Aloka). Mrp2-dependent uptake was calculated by subtracting the uptake into green fluorescent protein (GFP)-expressing vesicles (negative control) from uptake into Mrp2-expressing vesicles in the presence of 5 mM ATP (16) .
Cell culture and transport assay. Parental Madin-Darby canine kidney (MDCK) II cells and MDCK II cells expressing human MRP2
(MRP2-MDCK II) were kindly supplied by Dr. Piet Borst (The Netherlands Cancer Institutes, Amsterdam, The Netherlands) (11) . Cells were cultured in MEM (cat. no. M4655; Sigma) supplemented with 10% FBS at 37°C in the presence of 5% CO2. MRP2-MDCKII cells were maintained in the presence of 0.4 mg/ml geneticin (Sigma). Cells were seeded on plates with 24 wells at a density of 1.68 ϫ 10 5 cells per well. The cells were then cultured for 3 days to allow them to form polarized monolayers. GSH efflux assay was performed in HBSS (Life Technologies, Gaithersburg, MD) containing 0.5 mM acivicin (Sigma) at 37°C in the presence of 5% CO 2 (250 l/well). Samples (200 l) were taken and immediately mixed with ice-cold 25% metaphosphoric acid-0.1% EDTA (400 l) and then vortexed and stored at Ϫ20°C until analysis. At the end of the experiment, cells were disrupted with 1 ml 25% metaphosphoric acid-0.1% EDTA for 30 min at 37°C and then vortexed and stored at Ϫ20°C until analysis. HPLC analysis was performed as described above. For Statistical analysis. Statistical analysis was performed by Student's t-test or ANOVA followed by a post hoc test (Dunnett or Tukey) as described in the figure legends. Differences were considered to be statistically significant when P Ͻ 0.05.
RESULTS
Plasma concentration profile and biliary excretion of PCG. Elimination of [
3 H]PCG (180 mol/kg) from plasma followed typical two-exponential kinetics and was delayed in EHBR compared with SD rats (Fig. 1A) . In all, 31.7% of the radioisotope was recovered in the bile of SD rats until 60 min (Fig.  1B) . In a separate experiment, HPLC analysis revealed that only about half of the radioisotope recovered in the bile of SD rats was in the intact form (unpublished data), although we have not identified the metabolite(s) at present. As a result, 15% of the dose was recovered as intact PCG in the bile during 60 min, which was comparable with a previous report (18.7-23 .1% of the dose was recovered in intact form) (35) . On the other hand, only 4.3% of the radioisotope was recovered in the bile of EHBR over a 60-min period after [ 3 H]PCG administration (Fig. 1B) . These results indicate the role of Mrp2 in the biliary excretion of PCG and its metabolite(s) as well as their systemic elimination from the body.
Effect of PCG on the bile flow. The bile flow was transiently increased by 100% after PCG administration (180 mol/kg) in SD rats, whereas this was not observed in EHBR or salineinjected SD rats ( Fig. 2A) . The peak value of the bile flow was obtained at 10 min after the administration. This choleretic effect was similar to that in a previous report in which a 70% increase in bile flow was observed after intravenous administration of ampicillin (180 mol/kg) to Wistar rats, whereas no such effect was seen in Mrp2-deficient TR Ϫ rats (35) . These results indicate that Mrp2 is necessary for PCG-induced choleresis.
Effect of PCG on the biliary excretion of bilirubin and reduced glutathione. The biliary excretion of total bilirubin including conjugated (direct) and unconjugated (indirect) forms was transiently increased by 34% at 5 min after PCG administration in SD rats, and this higher level was maintained thereafter (Fig. 2B) . In EHBR, the biliary excretion rate was about half that of SD rats before PCG administration and gradually decreased after PCG administration (Fig. 2B) . The biliary excretion rate of GSH, which has recently been shown to be a low-affinity substrate of Mrp2, was dramatically increased by 210% after PCG administration, and its concentration in bile was increased despite the increase in bile volume (Fig. 2C) . That was not due to the altered degradation rate of GSH in the presence of millimolar concentration of PCG in the bile. Degradation rate constant of GSH in bile was not affected in the presence of 20 mM PCG at 37°C as determined by an in vitro experiment (0.298 Ϯ 0.11 and 0.326 Ϯ 0.05 min Ϫ1 in the absence and presence of 20 mM PCG, respectively). GSH in the bile from saline-treated SD rats was not altered during the experiment (Fig. 2C) . No GSH was detected in the bile of EHBR even after the PCG administration (data not shown).
The correlation between the biliary excretion rate of PCG or GSH and the bile flow rate are shown in Fig. 3 . The biliary excretion rate of PCG was correlated with the bile flow rate (r 2 ϭ 0.768; Fig. 3A) , although not all the points were on the Fig. 2 . PCG enhances biliary excretion of bilirubin, GSH, and exhibited choleresis in normal SD rats. PCG (180 mol/kg) or saline was intravenously administered to normal SD rats (F, PCG; OE, saline) and EHBR (E, PCG; ‚, saline) at time 0, and bile samples were analyzed to determine the bile flow rate (A), biliary excretion rate of total bilirubin (B), and GSH (C). GSH in the bile of EHBR was below the detection limit in both PCG-and saline-administered rats. Means Ϯ SD of 3-6 rats were plotted. *P Ͻ 0.05 and **P Ͻ 0.01, significantly different from the points before PCG administration (Ϫ5 min) using ANOVA followed by Dunnett's test.
linear line (0.72 mol⅐min Ϫ1 ⅐kg Ϫ1 vs. 89.4 l⅐min Ϫ1 ⅐kg Ϫ1 for the biliary excretion rate of PCG and bile flow at 5 min, respectively, indicated by the arrow in Fig. 3A) . On the other hand, the GSH excretion rate correlated fairly well with the bile flow rate as shown in Fig. 3B in the presence of 5 mM ATP that was ϳ10-fold higher than the uptake into control GFP-expressing vesicles (0.7 pmol⅐mg Ϫ1 ⅐2 min Ϫ1 ). However, neither Mrp2-dependent nor ATP-dependent uptake of [ 3 H]PCG was observed (Fig. 4) . Although several compounds are known to become substrates of MRP1 and MRP2 only in the presence of GSH, that was not the case for PCG, because no uptake was observed even in the presence of 5 mM GSH (data not shown). Mrp2-dependent [ 3 H]GSH uptake was not observed both in the absence or presence of 1 mM PCG as well (data not shown). These results indicate that PCG is not a substrate of Mrp2 or is a rather low-affinity substrate as reported for GSH (25) . We then examined the effect of PCG on the Mrp2 transport activity using a typical glutathione conjugate ([ 3 H]DNP-SG, 50 nM, 2 min) and glucuronide conjugate ([ 3 H]E 2 17␤G, 55 nM, 2 min) as substrates. Uptake into Mrp2-expressing vesicles was stimulated in the presence of ATP, whereas it was unaffected in the presence of AMP. Uptake into GFP-expressing vesicles was minor even in the presence of ATP and was unaffected by PCG (data omitted for clarity). ATP-dependent uptake of these substrates was significantly enhanced in the presence of PCG with maximum transport activity at 5 mM and 1 mM PCG for DNP-SG (492 Ϯ 51%) and E 2 17␤G (189 Ϯ 7.4%), respectively (Fig. 5 ). An inhibitory effect was observed in the presence of a high concentration of PCG (Fig. 5) . A similar for initial 2 min. Open and closed symbols are the uptake in the presence of 5 mM AMP and ATP, respectively. Uptake into GFP-expressing vesicles was minor even in the presence of ATP and was unaffected by PCG (data omitted for clarity). Means Ϯ SD of 3 studies were plotted. Where bars are not shown, the SD is contained within the limits of the symbols. effect was observed by using canalicular membrane vesicles (CMVs) isolated from SD rat liver (data not shown).
Effect of PCG on the efflux of GSH from MRP2-expressing cells. Transport of GSH by Mrp2 is hardly detectable in a standard membrane vesicle study, but its export has been observed in an intact cell system (11, 25) . To examine whether the GSH efflux mediated by Mrp2/MRP2 is stimulated by PCG, human MRP2-expressing MDCKII cells (MRP2-MDCKII) were used. In these cells, GSH export in the apical direction is enhanced and results in a lower intracellular GSH concentration as reported previously (11, 25) . In our experiment, the time-dependent GSH efflux over 2 h was also high compared with the parent MDCKII cells and was stimulated by 1 mM PCG (Fig. 6A ). This stimulatory effect was concentration dependent up to 10 mM (Fig. 6, B and C) . Accordingly, the intracellular GSH concentration was reduced in PCG-treated MRP2-MDCKII cells (Fig. 6B) . The total GSH (cell ϩ medium) recovered during the experiment was not affected (Fig.  6B) , indicating that the increase in the GSH efflux was achieved by enhanced efflux rather than accelerated synthesis of GSH. Such an effect was not observed, or was only minor, in parental cells.
Transcellular transport of PCG in MRP2-expressing cells. The possibility of the MRP2-mediated transport of PCG was further examined in an intact cell system at a concentration of 100 M. In a parental MDCKII cells, transport of [ 3 H]PCG in the basolateral-to-apical direction was somewhat higher than in the opposite direction, indicating an endogenous efflux carrier on the apical membrane or an uptake carrier on the basolateral membrane (Fig. 7A) . If PCG is a substrate of MRP2, vectorial transport in the basolateral-to-apical direction should be observed, because MRP2 localizes on the apical membrane. However, such preferential transport was not observed (Fig.  7B) . Transcellular transport clearance in the basolateral-toapical direction, calculated from the initial 0.5 to 1 h, was rather lower in MRP2-MDCKII cells compared with that in parental MDCKII cells (Table 1) . PCG remaining in the cells after 2-h exposure from the apical compartment were lower compared with those from the basolateral compartment (Table  1) . This also implies the presence of endogenous transporter(s) as described above.
DISCUSSION
Bile flow involves BSDF and BSIDF. These are produced by the active efflux of bile salts and reduced glutathione by BSEP and Mrp2, respectively. Cholestatic compounds such as cyclosporin A and PSC833 are potent inhibitors of these carriers as assessed by the membrane vesicle study and are the direct cause of cholestasis observed in in vivo situations (4, 5) . Some toxic compounds as well as hyperosmotic treatment are reported to affect canalicular localization of Mrp2 and/or BSEP by reducing the total bile flow (7, 10, 20, 21, 27) . However, to date, there is no example of a direct correlation between the stimulation of transport activity assessed in an in vitro membrane vesicle study and the in vivo choleretic effect. The compound itself may become a driving force if its concentration in the bile is high enough after the use of active efflux carriers. In the case of PCG, the highest biliary concentration is 20 mM, whereas it is 0.2 mM in the plasma at 10 min after concentration-dependent stimulation of the efflux of GSH from MDCKII (top graphs, n ϭ 3) and MRP2-MDCKII cells (bottom graphs, n ϭ 4). Cells were incubated for 2 h in the presence of the indicated concentration of PCG. GSH in the medium (open columns) and GSH remaining in the cell (filled columns) were analyzed by HPLC as described in MATERIALS AND METHODS. Total GSH (sum of the GSH exported and remaining in the cell at 2 h; F) was also plotted in the same figure. C: MRP2-dependent efflux of GSH. MRP2-dependent GSH efflux was calculated by subtracting the GSH efflux in MDCKII cells from that in MRP2-MDCKII cells as shown in B. Means Ϯ SD were plotted. Where bars are not shown, the SD is contained within the limits of the symbols. *P Ͻ 0.05 and **P Ͻ 0.01, significantly different from those in the absence of PCG as determined by Student's t-test.
PCG administration (Fig. 1) . Such a steep gradient likely causes the osmotic traction of water from the blood to the bile via the tight junctions of hepatocytes and cholangiocytes. If PCG excretion is directly related to choleresis, the choleretic index can be calculated as 21.8 l/mol PCG excreted into bile, and this is comparable with the other choleretics reported previously (13, 14, 36) . However, the biliary excretion of PCG itself was not exactly correlated with the bile flow rate (r 2 ϭ 0.768), suggesting that other transported ion(s) may be the additional driving force of the choleretic phenomenon. BSIDF is mainly produced by the excretion of GSH into the bile and is readily affected by some forms of drug treatment (2) . As shown in Fig. 3A , the biliary excretion of GSH correlated fairly well with the change in bile flow (r 2 ϭ 0.968). This indicates that the biliary excretion rate of GSH as well as PCG itself may be the driving force of bile flow after PCG administration. A similar choleretic effect mediated by the stimulation of GSH has been reported previously. Nifedipine (30 M), a Ca 2ϩ channel blocker used clinically, increased bile flow by 1.6-fold in the isolated perfused rat liver and is accompanied by enhanced biliary excretion of GSH (ϳ5-fold) (38) . Our in vivo correlation analysis and in vitro GSH export experiment suggested that the stimulation of GSH efflux as well as PCG excretion itself are involved in PCG-induced choleresis.
We were unable to detect any ATP-dependent transport in the recombinant Mrp2 expression system. We were also unable to detect any ATP-dependence or difference in the transport activity into CMVs isolated from SD rat and EHBR liver (data not shown) as reported previously (32) . Similarly, no ATPdependent transport of other ␤-lactam antibiotics including ampicillin and cefodizim was demonstrated, whereas the biliary excretion was significantly impaired in Mrp2-deficient rats (29, 35) . One of the possible reasons for this discrepancy is that these ␤-lactams are very poor substrates of Mrp2, hardly detectable in the membrane vesicle study. GSH is a typical example of this type of "poor" substrate. It has been reported that no ATP-dependent transport of GSH was detected in CMVs by using a standard protocol although its transport was readily detectable in an intact cell system (25) or under particular vesicle study conditions in which a reducing agent was omitted and an inert gas was added instead (26) . The other possibility is the lack of cofactor(s) for the recognition of PCG as a substrate. Some compounds, including chelerythrine, ␣-naphtylisothiocyanate, and arsenite are transported by Mrp2/ MRP2 in a reversible conjugation form with GSH (9, 22) . Such a cotransport mechanism with GSH or labile formation of GSH conjugate is, however, unlikely for PCG because: 1) fivefold excess PCG [including its metabolite(s)] over GSH was excreted in the bile of SD rats (Figs. 1B and 2C) , 2) 5 mM GSH did not stimulate [ 3 H]PCG transport in Mrp2-expressing vesicles (data not shown), and 3) apical preferential transport was not observed in MRP2-MDCKII cells in which sufficient amounts of intracellular GSH and exogenous MRP2 are equipped (Fig. 7, Table 1 ). Similarly, Zelcer et al. (39) reported that PCG transport was not observed in MRP2-expressing Sf9 cell membrane vesicles and MRP2-MDCKII cells. Still, we could not deny the presence of other unidentified endogenous cofactor(s) necessary for Mrp2/MRP2-mediated transport. The other possibility is that PCG is not a substrate of Mrp2/MRP2 and its absence in bile of EHBR is a secondary cause of Mrp2-deficiency. There are some compounds that are not substrates of Mrp2 but exhibit impaired biliary excretion in vivo. The biliary excretion of indocyanine green (ICG), a relatively hydrophobic anion, is significantly reduced in EHBR, whereas Mrp2 is not a major carrier of ICG. Inhibition of intracellular trafficking by endogenous bilirubin accumulated in hepatocytes may be the primary cause of the impaired biliary excretion in EHBR (29) . Supporting this hypothesis, biliary excretion of ICG was also diminished in Mdr2 knockout mice (15) whose plasma bilirubin concentration is elevated and Mrp2 expression is maintained (31). In our case, however, Transcellular transport clearance [apical-to-basolateral direction (A-to-B); basolateral-to-apical direction (B-to-A)] was calculated from the data shown in Fig. 7 . The initial transport velocity between 0.5 and 1 h was divided by the PCG concentration in the medium (100 M) to calculate the transport clearance. Intracellular PCG amount was measured at the end of the experiment (2 h). MRP, multidrug resistance-associated protein; MDCK, Madin-Darby canine kidney. *P Ͻ 0.05, †P Ͻ 0.01, significant difference. ANOVA followed by Tukey's test.
] [ ] bilirubin is not a major endogenous inhibitor of the biliary excretion pathway of PCG in EHBR liver; there was no biliary excretion of PCG in the EHBR liver perfusion study even after hepatic bilirubin was unloaded by preperfusion with 3% BSA for 60 min (unpublished observation). In any case, future studies need to be carried out to determine whether PCG is a substrate or merely a stimulator of Mrp2.
The stimulatory effect of PCG on the transport activity of the MRP family has been reported (1, 39) using membrane vesicles expressing MRP2. The transport of the glutathione conjugate of N-ethylmaleimide into MRP2-expressing membrane vesicles from Sf9 cells was stimulated by PCG in a concentration-dependent manner (maximum ϳ300% of the control in the presence of 5 mM PCG) (1) . . One of the possible reasons for these biphasic patterns may be the existence of a low-affinity interacting (of the order of mM) site for PCG. If PCG is a substrate of Mrp2, this low-affinity site could be a candidate transport site for PCG. Such a low-affinity site (K i ϭ 20 mM) has been reported for GSH (25) . The stimulatory effect of PCG on the efflux of GSH from MRP2-MDCKII strongly suggests that PCG interacts with MRP2 to stimulate its GSH transport activity. In this experimental cell system, PCG is not actively taken up without known specific carriers. The distribution volume of [ 3 H]PCG in MDCKII and MRP2-MDCKII at 2 h was as low as 2-3 l/mg (calculated from Table 1 ), which is similar to the distribution volume of water in the cell (23) . This results in an intracellular concentration of ϳ1 mM in the presence of 1 mM PCG in the medium for 2 h. Because PCG is a substrate of organic anion transporter-C/ SLC21A6 (33), double-transfected cells expressing the uptake carrier on the basolateral membrane and MRP2 on the apical membrane will be a valuable tool for detecting the transcellular transport of such hydrophilic compounds (28) . In contrast, specific carriers are reported to be involved in the hepatic uptake of PCG from blood (33, 34, 37) to achieve a higher concentration in hepatocytes. As a result, Mrp2-mediated GSH efflux could be stimulated by PCG to a substantial degree in vivo.
In conclusion, the choleretic effect of PCG is caused by the stimulation of biliary GSH efflux as well as the concentrative biliary excretion of PCG itself, both of which were Mrp2 dependent.
